Dianthus Therapeutics, Inc. (DNTH) is advancing its potential best-in-class complement inhibitor drug DNTH103 for a wide variety of autoimmune disorders. In particular, it is looking at advancing the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback